The study lasts about 72 weeks. People in the study are placed into different groups by chance, and neither the participants nor the study team know who receives RO7795068 or placebo during the study. Before treatment starts, a first check is done. After that, the medicine is given regularly, and follow-up visits continue through the study period to monitor weight, blood sugar, and overall health.

The study also looks at changes related to HbA1c, a blood test that shows average blood sugar over time, as well as waist size, blood pressure, cholesterol, and possible side effects. It also checks how the treatment may affect daily physical function and quality of life.

The purpose of the study is to see if the combination of BI 690517 and empagliflozin is more effective than empagliflozin alone in helping people with heart failure. Participants in the study will be randomly assigned to receive either the combination of BI 690517 and empagliflozin or a placebo and empagliflozin. The study will last for a period of 42 days, during which participants will take the medications orally, meaning they will swallow them in the form of tablets.

Throughout the study, researchers will monitor participants to see how the treatment affects their heart failure symptoms and overall health. The main focus will be on the time it takes for a participant to experience a serious heart-related event, such as a heart-related death or hospitalization due to heart failure. The study aims to provide valuable information on whether the new combination treatment can improve outcomes for people living with heart failure.

The purpose of the study is to evaluate how effective and safe these treatments are in achieving specific cholesterol level goals over a period of 12 weeks. Participants will be divided into different groups, with some receiving rosuvastatin alone and others receiving the combination of rosuvastatin and ezetimibe. The study will monitor changes in cholesterol levels at different intervals, specifically after 4, 8, and 12 weeks of treatment.

Throughout the study, participants will take the medications orally in the form of film-coated tablets. The trial aims to determine the proportion of patients who reach their LDL-C goals, which are set based on their risk levels for cardiovascular disease. The study will also assess the overall changes in cholesterol and other related blood fats to understand the effectiveness of the treatments. Participants’ adherence to the treatment regimen will be monitored to ensure accurate results.

The purpose of the study is to assess how effective these single-pill combinations are in reducing blood pressure after 16 weeks of treatment in patients with different grades of high blood pressure. Participants will take the medication orally, and the study will monitor changes in their blood pressure throughout the day and during office visits. The study will also look at how blood pressure varies over 24 hours and how well it is controlled during office visits.

Participants in the study will be monitored over a period of 16 weeks. During this time, they will have regular check-ups to measure their blood pressure and assess the effectiveness of the treatment. The study aims to provide valuable information on how these medications can help manage high blood pressure and improve overall health outcomes for patients with this condition.